Report ID: SQMIG35D2182
Report ID:
SQMIG35D2182 |
Region:
Global |
Published Date: August, 2024
Pages:
157
|
Tables:
96 |
Figures:
76
In April 2023, 3M’s modernized 3M™ Veraflo™ Therapy, got its first FDA clearance for hydromechanical elimination of infectious materials, wound debris, and non-variable tissue, which decreases the amount of surgical debridement needed, while helping granulation tissue formation, making a wound healing environment.
In July 2023, Coloplast signed a contract to purchase Kerecis, an emerging biologic wound care company for USD 1.3 billion. With this acquisition, Coloplast will increase its presence in the market with the help of Kerecis by entering high-growth, United States-centric biologics segment.
In May 2024, Convatec declared clinical study results from the latest multinational RCT (randomised controlled trial) presenting notable improvements in venous leg ulcers healing using AQUACEL® Ag+ Extra™ in comparison with the conventional dressing care.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35D2182